Target intelligence / Profile preview

RAD54-like protein 2 (RAD54L2)

Target
RAD54L2
Molecular classification
SNF2-family ATP-dependent DNA helicase, Chromatin remodeler, DNA-dependent ATPase, Transcriptional regulator
01

Overview

RAD54-like protein 2 (RAD54L2), also known as ARIP4, is an SNF2-family ATP-dependent DNA helicase and chromatin remodeler. It is fundamental in maintaining genome stability through its unique DNA damage avoidance pathway that regulates topoisomerase II (TOP2) turnover and suppresses formation of deleterious DNA adducts and recombination intermediates. RAD54L2 collaborates with factors like BLM/TOP3A/RMI1/RMI2 complexes, modulating post-replication repair, DNA damage response, and transcriptional regulation. It physically interacts with androgen receptor and is enriched at promoter regions needing rapid transcriptional induction, such as androgen-regulated genes. RAD54L2 deficiency sensitizes cells to chemotherapeutics targeting TOP2 due to enhanced persistence of TOP2-DNA adducts and chromosomal aberrations. Loss of RAD54L2 causes increased sister chromatid exchanges, decreased recombination repair fidelity, and heightened genome instability. Thus, RAD54L2 is a central guardian of chromatin integrity, cellular response to DNA damage, and is implicated in cancer biology, especially in relation to chemotherapy sensitivity.

Other names
Helicase ARIP4ARIP4KIAA0809SRISNF2LAndrogen receptor-interacting protein 4RAD54-like protein 2AR interacting protein 4HSPC325
02

Mechanism of action

Drugs such as etoposide and doxorubicin trap TOP2-DNA cleavage complex intermediates (TOP2ccs); RAD54L2 mediates removal/resolution of these adducts, reducing drug-induced genotoxicity and cell sensitivity. Loss of RAD54L2 sensitizes cells to these agents, indicating its role in DNA damage avoidance

03

Biological functions

DNA damage responseDNA recombination and repair, especially promoting noncrossover homologous recombination and suppressing sister chromatid exchangesChromosome segregationRegulation of chromatin accessibility, nucleosome organization, and transcription initiation (as a transcriptional regulator)Prevention/resolution of TOP2-linked DNA damage by promoting turnover of topoisomerase II (TOP2A/TOP2B) adductsR-loop resolution to enforce transcriptional progression of androgen-dependent genes
04

Disease associations

Genome instability disorders: deficiency increases sister chromatid exchanges and anaphase bridges, risk factors for chromosomal instability syndromesCancer: sensitivity to and modulation of chemotherapeutic agents such as TOP2 poisons (etoposide, doxorubicin, etc.)Potential role in androgen-mediated gene activation and prostate cancer biology due to interactions with androgen receptor
05

Safety considerations

RAD54L2 itself is an endogenous protein involved in genome maintenance, not a direct drug target in clinical use; however, drugs that target TOP2 pose risks of increased genotoxicity in the context of RAD54L2 deficiencyPotential therapeutic challenge: loss or mutation could increase risk of cytogenetic abnormalities and genome instability in normal cells
06

Interacting drugs

Doxorubicin

2 more in the full profile.

07

Biomarkers

RAD54L2 deficiency or expression as a marker of cellular response/sensitivity to TOP2-targeting chemotherapiesAccumulation of sister chromatid exchanges and anaphase bridges as indirect biomarkers of pathway integrity

Beyond the preview

Go deeper on RAD54-like protein 2 (RAD54L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAD54-like protein 2 (RAD54L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call